• Defining Immunotherapy Response with MSI-H and dMMR

    Comments are off for this post.

    Keytruda┬« (pembrolizumab), an immunotherapy, was approved by the FDA for patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors in May 2017. This was the first time a drug has been approved based on the results of a biomarker test for a genetic trait and not on the anatomical site of the … Read More